Health Canada Approves Celltrion’s Infliximab Biosimilar for Treatment of Rheumatoid Arthritis
By EsqSocial Corporation 03/02/21
Celltrion Healthcare Canada Limited announced yesterday that Health Canada granted a notice of compliance for Remsima SC®, an infliximab biosimilar of J& J’s Remicade®, for the treatment of adult patients with rheumatoid arthritis. Celltrion Senior Vice President Jovan Antunovic said the company is “delighted to bring the first subcutaneous form of infliximab to patients, payers and clinicians in Canada.”...
By: Goodwin